NPPB and myocardial infarction: In a large-animal post-MI model, two doses (day 3 intracoronary or intravenous, day 28 intravenous) at 1/5/10 mg·kg−1 improved EF (to ~44–45% with medium/high dosing), reduced LV end-systolic volume, interstitial fibrosis, and cardiomyocyte size, and lowered NT-proBNP versus placebo.